Patents Assigned to Crescendo Biologics Limited
  • Therapeutic molecules that bind to LAG3 and PD1
    Patent number: 11951172
    Abstract: The invention relates to LAG-3 binding agents, in particular variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: April 9, 2024
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, Angelica Sette, Isabelle Osuch, Yumin Teng, James Legg, David Escors Murugarren
  • Chimeric antigen receptor with single domain antibody
    Patent number: 11866510
    Abstract: The invention relates to chimeric antigen receptors (CAR) that comprise one or more single human variable domain antibody and cells that express such CAR. In particular, the invention relates to CARs that include multiple single human variable domain antibodies. In a particular embodiment, the one or more single human variable domain antibody binds to prostate membrane antigen.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: January 9, 2024
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Brian McGuinness, Colette Johnston
  • Single domain antibodies to programmed cell death (PD-1)
    Patent number: 11814429
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 14, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • Therapeutic molecules
    Patent number: 11746158
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: October 22, 2021
    Date of Patent: September 5, 2023
    Assignee: Crescendo Biologics Limited
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • IL-17A binding proteins
    Patent number: 11667705
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 6, 2023
    Assignee: Crescendo Biologics Limited
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • TRANSGENIC MICE
    Publication number: 20230133028
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the reproduction of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Application
    Filed: October 19, 2022
    Publication date: May 4, 2023
    Applicant: Crescendo Biologics Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • Single domain antibodies to programmed cell death protein 1 (PD-1)
    Patent number: 11591398
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: February 28, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • Therapeutic molecules binding PSMA
    Patent number: 11401342
    Abstract: The invention relates to improved binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: August 2, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Nikki Royle, Steve Vance, Viviane Zelenay
  • Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same
    Patent number: 11312771
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 26, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • Therapeutic molecules
    Patent number: 11236174
    Abstract: The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: February 1, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Brian McGuinness, Isabelle Osuch, Chris Rossant, Mike Romanos, Nikki Royle, Thomas Sandal, Lorraine Thompson, Michele Writer
  • Molecules that bind prostate specific membrane antigen (PSMA)
    Patent number: 10975161
    Abstract: The disclosure relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: April 13, 2021
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Eleanora Balloi, Normann Goodwin, Brian McGuinness, Chris Rossant, Thomas Sandal, Lorraine Thompson
  • Composition for treatment of disorders
    Patent number: 10947308
    Abstract: The invention relates to stable and non-aggregating compositions comprising an IL-17A binding molecule, in particular a single domain antibody. Such compositions are useful for topical administration in the treatment of disease, for example skin disease or asthma.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: March 16, 2021
    Assignee: Crescendo Biologics Limited
    Inventors: Karen Bannister, Ulla Lashmar, Daniel Pettit, Thomas Sandal
  • IL-17A binding proteins
    Patent number: 10654924
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 19, 2020
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • Methods for producing optimised therapeutic molecules
    Patent number: 10400030
    Abstract: The invention relates to a method of designing an immunoglobulin library for optimization of a biological property of a first lead immunoglobulin and libraries of optimized immunoglobulins produced by such methods.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: September 3, 2019
    Assignee: Crescendo Biologics Limited
    Inventors: Bryan Edwards, Yumin Teng
  • Mouse ? light chain locus
    Patent number: 10194645
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: February 5, 2019
    Assignee: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou
  • TRANSGENIC MICE
    Publication number: 20180362666
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Application
    Filed: October 22, 2014
    Publication date: December 20, 2018
    Applicant: Crescendo Biologics Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • METHODS FOR PRODUCING OPTIMISED THERAPEUTIC MOLECULES
    Publication number: 20180002403
    Abstract: The invention relates to a method of designing an immunoglobulin library for optimisation of a biological property of a first lead immunoglobulin and libraries of optimised immunoglobulins produced by such methods.
    Type: Application
    Filed: January 12, 2016
    Publication date: January 4, 2018
    Applicant: Crescendo Biologics Limited
    Inventors: Bryan EDWARDS, Yumin TENG
  • VH SCAFFOLD
    Publication number: 20170306319
    Abstract: The invention provides human VH scaffold sequences, libraries derived therefrom and methods of producing. The scaffolds have high expression, solubility and are functional.
    Type: Application
    Filed: October 22, 2014
    Publication date: October 26, 2017
    Applicant: Crescendo Biologics Limited
    Inventor: Bryan Edwards
  • HUMAN VH DOMAIN SCAFFOLDS
    Publication number: 20170306039
    Abstract: The invention provides human VH scaffold sequences, libraries derived therefrom and methods of producing. The scaffolds have high expression, solubility and are functional.
    Type: Application
    Filed: October 22, 2014
    Publication date: October 26, 2017
    Applicant: Crescendo Biologics Limited
    Inventors: Bryan Edwards, Mingyue He
  • MOUSE LAMBDA LIGHT CHAIN LOCUS
    Publication number: 20170049083
    Abstract: The present invention provides in a first aspect a mouse in which the ? (lambda) light chain locus has been functionally silenced. In one embodiment, the mouse ? light chain locus was functional silenced by deletion of gene segments coding for the ? light chain locus. In a further aspect, a mouse containing functionally silenced ? and ? (kappa) L chain loci was produced. The invention is useful for the production of antibodies, for example heterologous antibodies, including heavy chain only antibodies.
    Type: Application
    Filed: August 8, 2016
    Publication date: February 23, 2017
    Applicant: Crescendo Biologics Limited
    Inventors: Marianne Brüggemann, Xiangang Zou